PIQRAY® (alpelisib) FDA Approved for the Treatment of Patients with a PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer , Available Exclusively at Biologics by McKesson
Cary, N.C., August 7, 2025 – Effective June 15, PIQRAY® (alpelisib) is now exclusively available at Biologics by McKesson, an […]
VIJOICE® (alpelisib) FDA Approved for the Treatment of Patients with PIK3CA-Related Overgrowth Spectrum (PROS), Available Exclusively at Biologics by McKesson
Cary, N.C. , August 7, 2025 – Effective June 15, VIJOICE® (alpelisib) is now exclusively available at Biologics by McKesson, […]